Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.
Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA. Ayyagari R, et al. Among authors: chandiwana d. Curr Med Res Opin. 2018 Sep;34(9):1645-1652. doi: 10.1080/03007995.2018.1479246. Epub 2018 Jun 12. Curr Med Res Opin. 2018. PMID: 29781326
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D, Thabane ME, Park J, Chandiwana D, Delea TE. Stellato D, et al. Among authors: chandiwana d. Pharmacoeconomics. 2021 Sep;39(9):1045-1058. doi: 10.1007/s40273-021-01027-4. Epub 2021 Jun 9. Pharmacoeconomics. 2021. PMID: 34105083
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib + letrozole: results from MONALEESA-2.
Verma S, O'Shaughnessy J, Burris HA, Campone M, Alba E, Chandiwana D, Dalal AA, Sutradhar S, Monaco M, Janni W. Verma S, et al. Among authors: chandiwana d. Breast Cancer Res Treat. 2018 Aug;170(3):535-545. doi: 10.1007/s10549-018-4769-z. Epub 2018 Apr 13. Breast Cancer Res Treat. 2018. PMID: 29654415 Free PMC article. Clinical Trial.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study.
Fasching PA, Beck JT, Chan A, De Laurentiis M, Esteva FJ, Jerusalem G, Neven P, Pivot X, Bianchi GV, Martin M, Chandiwana D, Lanoue B, Ridolfi A, Wang Y, Rodriguez Lorenc K, Nusch A. Fasching PA, et al. Among authors: chandiwana d. Breast. 2020 Dec;54:148-154. doi: 10.1016/j.breast.2020.09.008. Epub 2020 Sep 23. Breast. 2020. PMID: 33065342 Free PMC article. Clinical Trial.
29 results